India to Sudan: Antitoxin Export Trade Route

To import Antitoxin formulations into Sudan, the following approvals and registrations are necessary:

1. Manufacturing Plant Registration: The manufacturing facility must be registered with the NMPB.

2. Product Registration: The Antitoxin formulation must be registered and freely sold in the country of origin. If not, a justification must be provided.

3. Application Submission: An application form, completed by the applicant, must be submitted along with the prescribed fees.

4. Documentation: All documents should be in English and include:

• Certificate of Pharmaceutical Product (CPP): Issued in the WHO format by the health authority in the exporting country, authenticated by the Sudanese Ministry of Foreign Affairs. The CPP should detail the active and inactive ingredients with their quantitative composition.

• Good Manufacturing Practice (GMP) Certificate: Issued by the competent authority in the country of origin, authenticated and stamped by the Sudanese Embassy.

• Statement of Licensing Status of Pharmaceutical Product (SLSPP): Conforming to the WHO-recommended format, issued by the certifying authority in the country of origin, and authenticated by the Sudanese Embassy.

5. Dossier Format: While the NMPB does not explicitly mandate the Common Technical Document (CTD) or electronic CTD (eCTD) format, the submission should include comprehensive product information, including manufacturing procedures, quality control specifications, and stability studies.

6. Timelines and Fees: Specific timelines for approval and product registration fees are not publicly detailed. It is advisable to consult directly with the NMPB or a local authorized agent for precise information.

7. GMP Inspection Requirements: The NMPB may require GMP inspections of foreign manufacturing facilities. Indian manufacturers should ensure their facilities comply with international GMP standards and be prepared for potential inspections.

Indian exporters of Antitoxin formulations must adhere to the following GMP certifications to supply products to Sudan:

1. WHO-GMP Certification: Manufacturing facilities must comply with WHO-GMP standards, ensuring products are consistently produced and controlled according to quality standards.

2. GMP Certificate Authentication: The GMP certificate must be issued by the competent authority in India, authenticated by the Sudanese Embassy.

3. Facility Approval: While specific lists of approved Indian facilities are not publicly available, manufacturers should ensure their facilities meet international GMP standards and maintain relevant documentation.

4. Regulatory Actions: There is no publicly available information on recent inspections or regulatory actions by the NMPB against Indian pharmaceutical companies. Manufacturers should maintain compliance with all regulatory requirements to avoid potential issues.

As of March 2026, there have been no publicly announced regulatory changes, new guidelines, mutual recognition agreements, or policy shifts affecting Indian pharmaceutical exports to Sudan in the past 18 months. Exporters should stay informed through official channels and maintain communication with local agents to ensure compliance with any future regulatory updates.

In summary, Indian exporters aiming to supply Antitoxin formulations to Sudan must ensure compliance with the NMPB's registration and import requirements, maintain adherence to WHO-GMP standards, and stay vigilant for any regulatory changes.

As of 2024, Sudan's importation of antisera and other blood fractions, which include antitoxin formulations, experienced a significant increase. This growth is primarily driven by the country's efforts to combat prevalent diseases requiring antitoxin treatments, such as tetanus and diphtheria. The demand is further bolstered by Sudan's expanding healthcare infrastructure and initiatives aimed at improving public health outcomes. While specific figures for domestic production of antitoxin formulations are limited, the substantial reliance on imports indicates that local manufacturing capacity is insufficient to meet the national demand.

Sudan maintains a 0% import duty rate for pharmaceutical products under HS code 30021220, encompassing finished antitoxin formulations. This exemption is part of Sudan's broader policy to facilitate access to essential medicines. Additionally, there are no value-added tax (VAT) or goods and services tax (GST) imposed on these pharmaceutical imports, further reducing the cost burden on healthcare providers and patients. Currently, there are no free trade agreements (FTAs) between Sudan and India that specifically affect pharmaceutical tariffs, nor are there any anti-dumping duties applied to these products.

In 2024, the primary suppliers of antisera and other blood fractions to Sudan were China, Turkey, and Switzerland, collectively accounting for a significant share of the imports. India's contribution, while notable, was comparatively smaller. The competitive landscape is influenced by factors such as pricing, quality standards, and the ability to meet Sudan's specific healthcare needs. Indian manufacturers are recognized for offering cost-effective antitoxin formulations, which positions them favorably against competitors from China and European Union countries. However, the overall market share is also affected by factors like logistical capabilities, regulatory compliance, and established trade relationships.

India is a global leader in the production of generic pharmaceuticals, accounting for approximately 20% of the global supply by volume. This extensive manufacturing capability extends to finished dosage forms containing Antitoxin, including tablets, capsules, syrups, and injections. The country's cost-effective production is attributed to economies of scale, a skilled workforce, and a well-established supply chain. As of 2025, India boasts over 1,400 WHO-GMP certified facilities and more than 800 US FDA-approved plants, ensuring high-quality standards in pharmaceutical manufacturing.

When comparing Antitoxin formulation exports, India offers a competitive edge over China and the European Union (EU). Indian manufacturers provide finished dosage forms at a lower price per unit due to efficient production processes and lower labor costs. The quality of Indian pharmaceuticals is well-regarded, with numerous facilities holding WHO-GMP and US FDA certifications. In contrast, while Chinese manufacturers have increased their presence in the generic formulations market, concerns about quality and regulatory compliance persist. The EU, known for its high-quality branded generics, often comes with a higher price point. In Sudan, Indian Antitoxin formulations are widely accepted, with a strong track record of regulatory compliance and supply reliability.

The India-Sudan supply chain for Antitoxin formulations has demonstrated reliability, supported by India's substantial manufacturing capacity. Facilities such as Taj Pharma India Ltd. have a monthly production capacity of 120 million tablets and 40 million capsules, ensuring the ability to meet large-scale demands. These facilities are equipped with advanced packaging and cold chain capabilities, essential for maintaining product integrity during transit. Indian manufacturers have a consistent record of regulatory compliance, with numerous plants holding WHO-GMP and US FDA approvals. There have been no significant supply disruptions reported in recent years, and manufacturers continue to expand their capacities to meet growing global demand.

For Sudanese buyers sourcing Antitoxin formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply chain.

• Minimum Order Quantities (MOQs): Be aware that MOQs can vary among manufacturers. Establish clear agreements on order sizes to align with both parties' logistical and financial considerations.

• Payment Terms: Standard payment terms in India-Sudan pharmaceutical trade often include letters of credit (LC) or advance payments. Negotiate terms that balance cash flow management with supplier trust.

• Supplier Qualification Process: Conduct thorough due diligence, including facility audits, verification of regulatory certifications (such as WHO-GMP and US FDA approvals), and assessment of production capabilities to ensure product quality and compliance.

• Regulatory Compliance: Ensure that selected suppliers have a strong track record of compliance with international regulatory standards to facilitate smooth importation and distribution within Sudan.

Before engaging with Indian manufacturers for antitoxin formulations, Sudanese buyers should adhere to the following pre-qualification steps:

When sourcing antitoxin formulations from Indian manufacturers, Sudanese buyers should request the following documents:

When evaluating Indian suppliers of antitoxin formulations, Sudanese buyers should be cautious of the following warning signs:

To ensure the quality and compliance of antitoxin formulations, Sudanese buyers should implement the following audit and monitoring procedures:

Cost Estimates and Timeline:

• Audit Visits to India:
• Plan for a 3-5 day on-site audit, with additional time for travel and reporting.
• Estimated costs include auditor fees, travel expenses, and accommodation, totaling approximately $5,000 to $10,000 USD per audit.

• Remote Monitoring:
• Costs vary based on the frequency and depth of virtual assessments but are generally lower than on-site audits.

Implementing these measures will help ensure that Sudanese buyers source high-quality antitoxin formulations from reputable Indian manufacturers, safeguarding public health and compliance with regulatory standards.